LPA and cardiovascular disorder: These promising outcomes and the lack of equally sufficient non-invasive approaches explain the fact that in Germany, since 2008, Lp(a) apheresis has been available for patients with elevated Lp(a) levels and established cardiovascular disease (CVD), even without elevated LDL levels [41].